Skip to main content
Clinical Trials/CTRI/2021/03/032021
CTRI/2021/03/032021
Not yet recruiting
未知

A Phase 2b study to determine the efficacy of probiotics given in peritransplant period among allogenic stem cell transplant recipients in preventing gram negative bacteremia, mortality, graft versus host disease

Christian Medical College Vellore0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Christian Medical College Vellore
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Christian Medical College Vellore

Eligibility Criteria

Inclusion Criteria

  • 1\) Age \>18 years.
  • 2\) Undergoing Allogenic Stem cell transplant in the Department of Haematology, CMC Vellore. 3\) Presence of CRO or ESBL organism in Pre\-transplant Fecal surveillance

Exclusion Criteria

  • 1\) Age \<18 years
  • 2\) Susceptible organisms in the Pre\-transplant Faecal surveillance.
  • 3\) Patients who already have an ongoing bacterial infection at the time of HSCT.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
A phase II study to evaluate the effectiveness of S-1 + Cetuximab for patients with advanced/recurrent colon cancer who cannot undergo intensive therapyadvanced/recurrent colon cancer patients with RAS wild-type tumors who cannot undergo intensive therapy
JPRN-UMIN000018484HO HOKKAIDO CANCER CENTER Division of Gastroenterology57
Recruiting
Not Applicable
The study evaluate the efficacy of intraoperative radiotherapy those who underwent neoadjuvant chemotherapy for pancreatic cancer.
KCT0005113Yonsei University Health System, Gangnam Severance Hospital80
Active, not recruiting
Phase 1
VAC071: A study to assess efficacy of the ChAd63/MVA PvDBP vaccinesPlasmodium vivax malariaMedDRA version: 20.0Level: LLTClassification code 10047665Term: Vivax malaria (benign tertian)System Organ Class: 100000004862Therapeutic area: Diseases [C] - Parasitic Diseases [C03]
EUCTR2019-000643-27-GBniversity of Oxford / Clinical Trials and Research Governance19
Completed
Phase 2
A phase II study to investigate the efficacy of neoadjuvant erlotinib in patients with clinical stage I/II non-small cell lung cancer (NSCLC)early stage lung cancernon-small cell lung cancer stage I/II10038666
NL-OMON29708Antoni van Leeuwenhoek Ziekenhuis55
Completed
Phase 2
Phase II Clinical Study Evaluating the Efficacy and Safety of Cetuximab Rechallenge in Patients with Wild-Type RAS, Unresectable, Progressive/Recurrent Colorectal Cancer Refractory to Fluoropyrimidines, Oxaliplatin, Irinotecan, Cetuximab and Bevacizumab: The E-Rechallenge TrialColorectal cancer
JPRN-UMIN000016439Public Health Research Foundation50